Company profile: Lin Bioscience
1.1 - Company Overview
Company description
- Provider of innovative drug therapies addressing unmet medical needs, developing: LBS-008, an oral treatment for dry age-related macular degeneration and Stargardt disease; LBS-007, a CDC7 inhibitor for leukemia and solid tumors; LBS-002, an anti-tubulin therapy for brain tumors that crosses the blood-brain barrier; and LBS-009, an oral therapy for NAFLD and type 2 diabetes.
Products and services
- LBS-002: A blood-brain barrier-permeable anti-tubulin therapy for primary and metastatic brain tumors that disrupts cancer cell division after crossing the blood-brain barrier
- LBS-007: A targeted therapy that inhibits the CDC7 protein to stop cancer cell replication across various cancers, including leukemia and solid tumors
- LBS-008: An oral therapy reducing retinol delivery to the eye to prevent toxic vitamin A by-product accumulation, treating dry age-related macular degeneration and Stargardt disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lin Bioscience
Altor BioScience
HQ: United States
Website
- Description: Provider of immunotherapeutic agents for cancer, viral infections, and autoimmune diseases, including ANKTIVA (N‑803), an IL‑15 receptor agonist for non‑muscle invasive bladder cancer; investigational cancer and viral therapies and vaccines (personalized neoepitope-based, HIV, HPV); Tri‑Ad5 vaccine for Lynch syndrome; STAR Fusion reagents for diagnosis/targeting, STAR Multimer reagents for research; and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altor BioScience company profile →
Glycotope
HQ: Germany
Website
- Description: Provider of GMP-compliant contract manufacturing for active biopharmaceutical ingredients (proteins and antibodies) via recombinant production, and oncology antibody solutions including GT-001 (Lewis Y), GT-002 (LYPD3), GT-00A (MUC1) and an IL-15 immuno-cytokine, plus GlycoTarget Discovery and a platform enabling high tumor-specificity by targeting tumor-associated carbohydrates for ADC/CAR development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Glycotope company profile →
Pharmion
HQ: United States
Website
- Description: Provider of products for the treatment of hematology and oncology patients, focused on acquisition, development, and commercialization. Global biotech partnering with scientific and clinical advisors to identify and develop products for hematology and oncology markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmion company profile →
Microvascular Tissues
HQ: United States
Website
- Description: Provider of biological vascular tissues for implantation, including mVASC Microvascular Tissue, a sterile, off-the-shelf human microvascular tissue graft designed to restore blood flow and support natural healing in damaged tissues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microvascular Tissues company profile →
Annovation BioPharma
HQ: United States
Website
- Description: Provider of pharmaceutical products focused on anesthesia, sedation and sleep; incorporated in 2009 and based in Wayland, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Annovation BioPharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lin Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lin Bioscience
2.2 - Growth funds investing in similar companies to Lin Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lin Bioscience
4.2 - Public trading comparable groups for Lin Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →